| Ytd | 222.35% | |
| 1y | 171.36% |
| Open | 101.16 | Prev Close | 102.88 | Low | 99.91 | High | 104.65 | Mkt Cap | 6.37B |
| Vol | 1.50M | Avg Vol | 1.71M | EPS | -1.32 | P/E | N/A | Forward P/E | -134.78 |
| Beta | 2.21 | Short Ratio | 9.72 | Inst. Own | 123.83% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-03 | 50-d Avg | 68.89 | 200-d Avg | 45.98 | 1yr Est | 74.10 |
Guggenheim analyst Subbu Nambi maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and rais
https://www.sec.gov/Archives/edgar/data/1581280/000110465926075726/tm2617605-1_s3asr.htm
TD Cowen analyst Brendan Smith maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the
Canaccord Genuity analyst Kyle Mikson initiates coverage on Twist Bioscience (NASDAQ:TWST) with a
Piper Sandler analyst David Westenberg initiates coverage on Twist Bioscience (NASDAQ:TWST) with